eTheRNA immunotherapies Funding: $104M Raised, Series B
eTheRNA immunotherapies is based in Niel, Belgium. It has raised $104M in total funding. Latest round: Series B. Backed by PMV, LSP, Boehringer Ingelheim.
eTheRNA immunotherapies funding overview
eTheRNA immunotherapies is based in Niel, Belgium. eTheRNA immunotherapies has raised $104M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in August 2022. The round record for eTheRNA immunotherapies runs through 2022; nothing later has been disclosed. Investors on record include PMV, LSP, Boehringer Ingelheim, Fund+, Omega Funds, Grand Decade and 2 others. 8 distinct backers are named across the disclosed rounds.
Frequently asked about eTheRNA immunotherapies funding
How much has eTheRNA immunotherapies raised?
eTheRNA immunotherapies has raised $104M in total disclosed funding across the rounds on record.
Who has invested in eTheRNA immunotherapies?
PMV, LSP, Boehringer Ingelheim, Fund+, Omega Funds, Grand Decade are named among the investors backing eTheRNA immunotherapies.
What was the latest eTheRNA immunotherapies funding round?
The most recent disclosed round is a Series B, announced in August 2022.
Where is eTheRNA immunotherapies based?
eTheRNA immunotherapies is based in Niel, Belgium.
When did eTheRNA immunotherapies last raise?
The last disclosed eTheRNA immunotherapies round closed in August 2022 at Series B.
Every eTheRNA immunotherapies figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Niel at a similar stage.
